Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China
Golden Age Health and Innostellar team up on a 10-year pact to bring sight-saving LX-101 gene therapy to China, aiming to help RPE65 IRD patients 'see the future, clearly.'
'Partnering with Innostellar positions GAH at the forefront of gene therapy in China's rapidly expanding ophthalmology market,' said Francis Wan, Chief Executive Officer of Golden Age Health. 'Our integrated approach aims to deliver sight-saving innovation to patients swiftly and comprehensively.'
Dr Wang Fenghua, Founder & CEO of Innostellar, added: 'By joining forces with GAH, we can ensure LX-101 reaches patients across China rapidly and—crucially—at prices families can afford, thanks to efficiencies gained through local development and manufacturing. Improving patient access lies at the heart of our mission.
About Inherited Retinal Dystrophies
Inherited retinal dystrophies (IRDs)—including retinitis pigmentosa (RP) —are genetic disorders that progressively destroy photoreceptors, leading to severe vision impairment or blindness, often from childhood. RP affects approximately 1 in 3,000–4,000 people worldwide and is officially listed in China's National Rare Disease Catalog (first list, 2018), underscoring the country's commitment to improving outcomes for affected patients.
About LX-101
LX-101 is an adeno-associated-virus (AAV) gene therapy delivering a functional RPE65 gene directly to retinal cells, aiming to restore the visual cycle in patients with biallelic RPE65-mutation IRDs. The programme is in Phase III clinical development in China, with top-line results expected in Q4 2025 and initiate NMPA New Drug Application soon after. If approved, LX-101 would provide eligible patients with a single-dose, durable treatment designed to halt—or potentially reverse—vision loss.
About Golden Age Health
Golden Age Health is a specialty pharmaceutical company dedicated to redefining patient access to medicine across China, Asia-Pacific and beyond. Headquartered in Singapore, GAH pairs data-driven market-access expertise with deep medical-affairs and RWE capabilities to bring high-impact therapies to underserved populations.
About Innostellar Biotherapeutics
Innostellar Biotherapeutics is a Shanghai-based biotechnology firm advancing innovative gene-therapy medicines for ocular and other genetic diseases and chronic diseases. Its pipeline is led by LX-101, the first gene therapy of its kind to enter late-stage development in China.
Forward-Looking Statements
This release contains forward-looking statements, including expectations regarding clinical development, regulatory approvals and commercial launches. These statements involve risks and uncertainties that may cause actual outcomes to differ materially.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
a day ago
- Hamilton Spectator
More High-Grade Antimony Intersected
ROUYN-NORANDA, Quebec, July 28, 2025 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to inform shareholders that Antimony Resources Corp. (ATMY-CSE, K8J0-FSE) has reported additional high-grade antimony intersections in drilling at the Bald Hill Property in New Brunswick under option from Globex. Highlights include the following: Hole BH-25-05 returned 1.1% antimony (Sb) over 14.5 metres at a depth of 108.8 m to 123.3 m downhole. Hole BH-25-08 returned 14.91% antimony (Sb) over 3.0 metres at a depth from 88.8 m to 91.8 m downhole including massive stibnite which returned 28.76% Sb over 1.7 metres. Hole BH-25-09 returned 9.85% antimony (Sb) over 4.3 metres at a depth from 103.6 m to 107.9 m downhole including 18.19% Sb from 104.6 m to 106.4 m downhole. The reported drill hole intersections are estimated to be between 75% to 80% of true width. A total of 3,150 metres have been completed in the 2025 drill campaign. Assays are pending and are expected to be received in the next three to four weeks. As reported in a press release dated July 16, 2025 , Antimony Resources have completed 16 drill holes which have outlined mineralization over 400 metres of strike length with the mineralization remaining open both along strike and down dip. Over 1,500 samples were submitted for assay. Previous reported drill results included from holes BH-25-03 and BH-25-04 which encountered respectively 2.76% Sb over 2.8 m from 78.2 m to 81.0 m and 4.17% Sb over 7.40 m from 106.6 m to 114.0m. Holes BH-25-01 and BH-25-02 were terminated short of the target and were redrilled by holes BH-25-08 and BH-25-09 which are subject of today's release of assays. Shareholders may access the Antimony Resources press release by clicking here . Needless to say, Globex is very pleased by the drill results to date and looks forward to additional assays being received. Location of the drill holes and surface occurrences – Antimony Resources This press release was written by Jack Stoch, P. Geo., President and CEO of Globex in his capacity as a Qualified Person (Q.P.) under NI 43-101. Forward-Looking Statements: Except for historical information, this news release may contain certain 'forward-looking statements'. These statements may involve a number of known and unknown risks and uncertainties and other factors that may cause the actual results, level of activity and performance to be materially different from the expectations and projections of Globex Mining Enterprises Inc. ('Globex'). No assurance can be given that any events anticipated by the forward-looking information will transpire or occur, or if any of them do so, what benefits Globex will derive therefrom. A more detailed discussion of the risks is available in the 'Annual Information Form' filed by Globex on 56,095,636 shares issued and outstanding A photo accompanying this announcement is available at
Business Wire
a day ago
- Business Wire
MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC). Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor. Ateganosine is a first-in-class small molecule that compromises telomere structure and function in cancer cells, leading to rapid tumor cell elimination and specific immune memory. Through telomerase-mediated action, ateganosine reverses intrinsic or acquired resistance to immune checkpoint inhibitors (ICIs). 'FDA's Fast Track Designation recognizes ateganosine's potential as a new therapeutic paradigm in cancer treatment science. Ateganosine is the first and only anticancer treatment of its kind that we are aware of in clinical development,' stated MAIA Chairman and CEO Vlad Vitoc, M.D. 'If we are successful in the Fast Track regulatory pathway, ateganosine could qualify for accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year. If approved, ateganosine would have a first-to-market competitive position within a $34 billion NSCLC treatment market with significant unmet medical need.' NSCLC represents one of the largest global oncology indications. The market was valued at $34.1B in 2024 and is projected to reach $68.8B by 2033 with a projected CAGR of 8.1%. 1 'This is an important milestone for MAIA's clinical development program. Ateganosine has demonstrated robust preclinical efficacy and superior clinical median overall survival compared to other FDA-approved treatments for NSCLC patients with prior disease progression on platinum-based chemotherapy and anti-PD-(L)1 antibody. Additionally, advanced NSCLC is a devastating disease that clearly meets the criteria for a serious condition with unmet medical need. Both are key criteria for the Fast Track designation,' said K. Robinson Lewis, Vice President, Head of Regulatory and Quality at MAIA. 'We intend to utilize the incentives of the Fast Track Program to expedite the development and review of ateganosine and bring patient access sooner.' The FDA Fast Track is a process designed to facilitate development and expedite the review of drugs for treating serious conditions and filling an unmet medical need, as in providing a therapy where none exists or which may be potentially better than available therapy. If relevant criteria are met during the Fast Track process, a drug will be eligible for FDA Accelerated Approval and Priority Review (FDA decision within six months). MAIA's most recent data from the pivotal Phase 2 THIO-101 clinical trial of ateganosine as of May 15, 2025 showed median overall survival (OS) of 17.8 months in a heavily pre-treated population. As of the data cut-off date, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care chemotherapy treatments for NSCLC in a similar setting have shown overall survival of 5 to 6 months. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About THIO-101 Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
Hamilton Spectator
a day ago
- Hamilton Spectator
Aventis Energy Announces Intent to Complete NI 43-101 Technical Report on the Sting Copper Project
Sting Project Highlights including 2024 Drilling Program (see company news release January 14, 2025): VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) — Aventis Energy ('Aventis' or the 'Company') (CSE:AVE | FRA:C0O0 | OTC: VBAMF) is pleased to announce that it has contracted Dahrouge Geological Consulting Ltd. ('Dahrouge') to complete a Technical Report (the 'Report') in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects on the Sting Copper Project ('Sting' or the 'Project') located in western Newfoundland, Canada. Dahrouge and its predecessor, Halferdahl and Associates Ltd., have advised and assisted clients in identifying, exploring, and developing mineral projects since 1971. Dahrouge's team of geologists and dedicated support staff continue to build a fifty-year legacy, handling projects of all scopes from grassroots exploration, to resource delineation, to prefeasibility and feasibility level studies and are currently recognized worldwide for their expertise in the exploration and discovery of 'critical' elements. Mandeep Parmar, Interim Chief Executive Officer & Director of the Company, commented, 'Our intention to complete a 43-101 Technical Report on the Sting Project represents a key inflection point in our Company's growth. We are confident that after the completion of the Report, guided by the expertise of Dahrouge, that we will be able to drive further advancement at Sting by way of future exploration and drilling programs.' The purpose of the Report is to provide a comprehensive update on the Project including all available historical data that the Company has gathered, in addition to strong copper grades retrieved from the fall 2024 drill program. The Report will offer valuable insights by compiling existing data, previous work, and new technology to better guide future programs. Figure 1: Sting Copper Project 2024 drilling results overview. Chargeability results at 100m depth. Qualified Person Statement The scientific and technical information contained in this news release has been reviewed, verified, and approved by Alexander Timofeev, Ph.D., of Dahrouge Geological Consulting, who is a registered in Quebec and Newfoundland, Canada and a 'qualified person' as defined in NI 43-101 – Standards of Disclosure in Mineral Projects. Historical data disclosed in this news release relating to sampling results from previous operators are historical in nature. Neither the Company nor a qualified person has yet verified this data and therefore investors should not place undue reliance on such data. The Company's future exploration work may include verification of the data. The Company considers historical results to be relevant as an exploration guide and to assess the mineralization as well as economic potential of exploration projects. Any historical grab samples disclosed are selected samples and may not represent true underlying mineralization. References *All assessment file data referenced above can be sourced at the following Newfoundland and Labrador web link: , 1 Hatch, 1922, (Assessment File 012G/08/0002) 2 Dean, 1980, (Assessment File 012G/08/0075) 3 Dean, 1977, (Assessment File 012G/08/0069) About Aventis Energy Inc. Aventis Energy Inc. (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is a mineral exploration company dedicated to the development of strategic projects comprised of battery, base and precious metals in stable jurisdictions. The Company is working to advance its Corvo Uranium & Sting Copper Project. The Corvo Uranium property has historical drill holes intersected multiple intervals of uranium mineralization, notably along a strike length of 800 metres between historical drill holes TL-79-3 (0.116% U 3 O 8 over 1.05 m) and TL-79-5 (0.065% U 3 O 8 over 0.15 m) 2 . High-grade* Uranium at Surface with the Manhattan showing (1.19 to 5.98% U 3 O 8 ) and SMDI showing 2052 (0.137% U 3 O 8 and 2,300 ppm Th). The Sting Copper Project covers approximately 3,700 hectares and recently had results of 54.8m at 0.32% Cu starting at a depth of 27.0m in 2024 drill hole VB24-001, with higher-grade intervals including six samples (≥0.5m length) ranging from 0.96% to 5.43% Cu. High grade samples of 0.5m at 2.85% Cu and 0.5m at 1.92% Cu with an additional broader interval of 31.1m at 0.27% Cu were found in VB24-003. On Behalf of the Board of Directors Mandeep Parmar Interim Chief Executive Officer, Director +1 (604) 229-9772 info@ Disclaimer for Forward-Looking Information This news release includes certain 'Forward-Looking Statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995 and 'forward-looking information' under applicable Canadian securities laws. When used in this news release, the words 'anticipate', 'believe', 'estimate', expect', 'target', 'plan', 'forecast', 'may', 'would', 'could', 'schedule' and similar words or expressions, identify forward-looking statements or information. Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Aventis, future growth potential for Aventis and its business, and future exploration plans are based on management's reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management's experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of uranium, copper, gold and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Aventis' ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms. This news release contains 'forward-looking information' within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company's objectives, goals, or future plans with respect to the Project; statements with respect to the Program; completion of the Report; expected benefits of the Report; and the Company's anticipated exploration program at the Project. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of uranium, copper, gold and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release. A photo accompanying this announcement is available at
